OncoMatch/Clinical Trials/NCT06615479

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Is NCT06615479 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for relapsed or refractory multiple myeloma (rrmm).

Phase 3RecruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06615479Data as of May 2026

Treatment: BMS-986393 · Cyclophosphamide · Fludarabine · Daratumumab · Pomalidomide · Dexamethasone · Carfilzomib — The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 3 prior lines

Min 1 prior line

Must have received: lenalidomide (lenalidomide)

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Alabama at Birmingham · Birmingham, Alabama
UCLA Hematology/Oncology - Santa Monica · Los Angeles, California
Local Institution - 0050 · Orange, California
Local Institution - 0223 · Washington D.C., District of Columbia
Baptist MD Anderson Cancer Center · Jacksonville, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify